anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
FIELD: medicine. SUBSTANCE: preparation is a mixture of substances involving interleukin-2 at concentration 1 wt.-% not above, bioactive cytokines at concentrations corresponding natural ratio, mixture of α- and b-chains of hemoglobin, impurities of nonidentified structure prepared from mammal mononuclear blood cells by their stimulation with activating addition of Ca-ionophore (concentration is 1-1000 ng/ml) and phorbol-12-myristate-13-acetate (concentration is 1-100 ng/ml) followed by cultivation and isolation from supernatant by a single step of liquid chromatography. Preparation can contain fetuin (concentration is 0.5-10 wt.-%) in the case of addition of activating additions of fetal serum to the composition. Preferable cell concentration in cultural fluid is 0.5-10 mln/ml, desirable cultivation time is 1-120 hr. Eluent used at liquid chromatography is 0.01 M trifluoroacetic acid solution or 15, 30 and 60% acetonitrile solution in 0.01 M aqueous trifluoroacetic acid solution. After separation of supernatant mononuclear cells were preferably to be stimulated repeatedly with activating additions. Proposed preparation shows the following advantages: high immunomodulating activity, the presence of natural carriers (a- and b -chains of hemoglobin), multicomponent nature of preparation excludes the necessity of selection and addition of recombinant cytokines, simple technology of preparing, absence of antibiotics in the process of its preparing that increases raw activity, possibility for repeated use of mononuclear cells. EFFECT: enhanced quality of preparation. 6 cl, 5 dwg
Root-knot nematode (Meloidogyne incognita) causes severe crop damage and large economic losses worldwide. Several cultivars of sweetpotato [Ipomoea batatas (L.) Lam)] have been developed with root-knot nematode-resistant traits; however, many of these cultivars do not have favorable agronomic characteristics. To understand the genetic traits underlying M. incognita resistance in sweetpotato, whole genome resequencing was conducted on three RKN-susceptible (Dahomi, Shinhwangmi, and Yulmi) and three RKN-resistant (Danjami, Pungwonmi, and Juhwangmi) sweetpotato cultivars. Three SNPs (single nucleotide polymorphisms) in promotor sequences were shared in RKN-resistant cultivars and were correlated with disease resistance. One of these SNPs was located in G6617|TU10904, which encoded a homolog of RIBOSOMAL PROTEIN EL15Z, and was associated with reduced expression in RKN-resistant cultivars only. Alongside SNP analysis, mRNA-seq data were analyzed for the same cultivars with and without nematode infection, and 18 nematode-sensitive genes were identified that responded in a cultivar-specific manner. Of these genes, expression of G8735|TU14367 was lower in sensitive cultivars than in RKN-resistant cultivars. Overall, this study identified two genes that potentially have key roles in the regulation of nematode resistance and will be useful targets for nematode resistance breeding programs.
This invention belongs to the field of medical technology. it reveals in detail a Chinese traditional medicinal powder for hemostasia, acesodyne, myogenic, sore healing. Shares of the amount by weight is: longan seed(1-100), Chinese insect wax(1-100), Radix Notoginseng(10-80), dragon's bone(10-50)which has the performancr of hemostasia, acesodyne, myogenic, sore healing. The invention also reveals the preparing method fo the above medince. Clinical applications have proved that this invention adopt the method of applying medicine to the diseased region can make the action of medicine directly reach to the diseased part with strong pertinence, high utilization of the effective components, fast affecting, short period of treatment, can provide obvious actions of hemostasis, relieving pains, promoting tissue regeneration and wound healing. It can used for treating wound, bleeding, pains, unhealing up after open cut operation, and the bleedings of mucous membrane of nasal cavity, anal canal and skin.
Patients meeting the criteria are randomized before discharge from the hospital and continued aspirin 100 mg qd and ticagrelor 90mg bid. The administration shall last 12 months.
Acute mountain sickness (AMS) represents a considerable issue for individuals sojourning to high altitudes with systemic hypoxemia known to be intimately involved in its development. Based on recent evidence that ketone ester (KE) intake attenuates hypoxemia, we investigated whether exogenous ketosis might mitigate AMS development and identified underlying physiological mechanisms. Fourteen healthy, male participants were enrolled in two 29-h protocols (simulated altitude of 4,000-4,500 m) receiving either KE or a placebo (CON) at regular timepoints throughout the protocol in a randomized, crossover manner. Physiological responses were characterized after 15 min and 4 h in hypoxia, and the protocol was terminated prematurely upon development of severe AMS (Lake Louise Score ≥ 10). KE ingestion induced a consistent diurnal ketosis (d-β-hydroxybutyrate, [βHB] of ∼3 mM), whereas blood [βHB] remained low (<0.6 mM) in CON. Each participant tolerated the protocol equally long or longer (n = 6 or n = 8, respectively) in KE. Protocol duration increased by 32% on average with KE, and doubled upon KE for severe AMS-developing participants (n = 9). Relative to CON, KE induced a mild metabolic acidosis, hyperventilation, and relative sympathetic dominance. KE also inhibited the progressive hypoxemia that was observed between 15 min and 4 h in hypoxia in CON, while concomitantly increasing cerebral oxygenation and capillary Po2 within this timeframe despite a KE-induced reduction in cerebral oxygen supply. These data indicate that exogenous ketosis attenuates AMS development. The key underlying mechanisms include improved arterial and cerebral oxygenation, in combination with lowered cerebral blood flow and oxygen delivery, and increased sympathetic dominance.NEW & NOTEWORTHY Ketone ester intake attenuated the development of acute mountain sickness at a simulated altitude of 4,000-4,500 m. This likely resulted from a mitigation of arterial and cerebral hypoxemia, reduced cerebral blood flow, and increased sympathetic drive.
Fever of unknown origin (FUO) is a relatively common pediatric complaint. The time of FUO generally ranges from 10 to 21 days. Generally the fever should be greater than 38.3 ˚c for at least 10 days with no evident source after initial outpatient or inpatient workup. A broad range of illnesses are known to cause FUO, including infectious, autoimmune and oncologic etiologies. Definitive diagnosis of FUO can be challenging, with many cases resolving spontaneously without a diagnosis. There is currently no standardized diagnostic approach for working up FUO. The general direction of the workup often depends on the patient's presentation, symptoms, and environmental exposures. It is generally accepted that a complete history and physical examination as well as basic laboratory tests, and empiric antibiotic therapy are initial steps in the workup of FUO. With no advanced resources available, radiographs such as chest X-rays and abdominal ultrasonography as well as simple tests e.g. ESR are commonly performed looking for infectious and malignant sources of FUO. If the diagnosis is still obscure laboratory tests for auto immune antibodies or specific infectious agents, are additional logical steps if the diagnosis remains in question.

Unlike adult studies, the categorical distribution of diagnosis of the causes of FUO in pediatrics has not changed in recent decades (Nield\&Kamat , 2018) \[1\]. Additional studies are needed to improve the recognition of causes of prolonged fever in children.

So that FUO is not a single specific medical disorder but may be a potential manifestation of several diseases and disorders. The initial approach to FUO is suggested to be determination of the causes of prolonged fever in each of the body systems, as suggested by the presenting complaint. For instance in the respiratory system in developing countries tuberculosis (TB) must be searched for in the first place. Similarly Protein Energy Malnutrition (PEM), and vitamin D deficiency rickets must be also thought of as a cause of recurrent / chronic chest infection leading to FUO. In the gastrointestinal system persistant/ recurrent diarrhea must be searched for. In the developing countries, urinary tract infection, typhoid fever and viral hepatitis constitute other hidden causes of FUO. Collagen diseases, auto inflammatory diseases as well as immune deficiency diseases and auto immune disorders must be searched for as causes of FUO.
Children who are HIV-exposed but uninfected have increased infectious mortality compared to HIV-unexposed children, raising the possibility of immune abnormalities following exposure to maternal viraemia, immune dysfunction, and co-infections during pregnancy. In a secondary analysis of the SHINE trial in rural Zimbabwe we explored biological pathways underlying infant mortality, and maternal factors shaping immune development in HIV-exposed uninfected infants. Maternal inflammation and cytomegalovirus viraemia were independently associated with infant deaths: mortality doubled for each log10 rise in maternal C-reactive protein (adjusted hazard ratio (aHR) 2.09; 95% CI 1.33-3.27), and increased 1.6-fold for each log10 rise in maternal cytomegalovirus viral load (aHR 1.62; 95% CI 1.11-2.36). In girls, mortality was more strongly associated with maternal C-reactive protein than cytomegalovirus; in boys, mortality was more strongly associated with cytomegalovirus than C-reactive protein. At age one month, HIV-exposed uninfected infants had a distinct immune milieu, characterised by raised soluble CD14 and an altered CD8 + T-cell compartment. Alterations in immunophenotype and systemic inflammation were generally greater in boys than girls. Collectively, these findings show how the pregnancy immune environment in women with HIV underlies mortality and immune development in their offspring in a sex-differentiated manner, and highlights potential new intervention strategies to transform outcomes of HIV-exposed children. ClinicalTrials.gov/NCT01824940.
Functional dyspepsia (FD) is known to be influenced by gut microbiota (GM) and circulating inflammatory proteins (CIPs), however, the causal relationship between GM, CIPs and FD haven't been investigated. This study employed two-sample Mendelian Randomization (TSMR) to investigate their associations using data from Genome-Wide Association Studies (GWAS). In this study, Inverse-variance weighted (IVW) method was employed as the primary analysis, with supplementary approaches including weighted median, weighted mode, simple mode, and MR-Egger. Heterogeneity and pleiotropy were assessed using the Cochrane Q test, MR-Egger intercept test, and MR-PRESSO global test. Totally, 196 GM traits and 91 CIPs were analyzed, and the results uncovered the causal impact of 12 GM taxa and 5 proteins on functional dyspepsia (FD). 9 GM genera were linked to a reduced risk of FD, while 3 GM genera were associated with an increased risk of FD.Additionally, reverse analysis revealed no FD-GM causation. Furthermore, IL-12, IL-10, CXCL10, CXCL9 and VEGFA were significantly correlated with FD, with CXCL9 and VEGFA acting as mediators in the association between GM traits and FD. Taken together, our findings established a link between specific GM and CIPs in the pathogenesis of FD, offering novel insights for its diagnosis and treatment.
Dual blockade of the RAS with angiotensin receptor blockers, ACE inhibitors, or aliskiren is associated with increased risks of hypotension, hyperkalemia, and changes in renal function (including acute renal failure) compared to monotherapy.

The VA NEPHRON trial enrolled 1,448 patients with type 2 diabetes, elevated urinary-albumin-to-creatinine ratio, and decreased estimated glomerular filtration rate (GFR 30 mL/min to 89.9 mL/min), randomized them to lisinopril or placebo on a background of losartan therapy and followed them for a median of 2.2 years. Patients receiving the combination of losartan and lisinopril did not obtain any additional benefit compared to monotherapy for the combined endpoint of decline in GFR, end state renal disease, or death, but experienced an increased incidence of hyperkalemia and acute kidney injury compared with the monotherapy group.

In general, avoid combined use of RAS inhibitors. Closely monitor blood pressure, renal function and electrolytes in patients on Zestril and other agents that affect the RAS.

Do not co-administer aliskiren with Zestril in patients with diabetes. Avoid use of aliskiren with Zestril in patients with renal impairment (GFR <60 mL/min).
Non-small cell lung cancer is the most common cause of cancer death globally. When apparent incidental pathogenic germline variants (PGVs) are uncovered with routine next generation sequencing (NGS) of NSCLCs, germline testing (GT) is recommended to confirm that PGV. Because it is far more common that an uncovered tumor TP53 variant is related to a somatic event than an incidental PGV, however, GT for Li Fraumeni syndrome (LFS) is not recommended based solely on uncovering a NSCLC TP53 variant. Because nearly all tumor EGFR variants are also somatic in origin, GT is not recommended based solely on uncovering a tumor EGFR variant.However, there is evidence that patients with coexisting NSCLC variants in both EGFR and TP53 have significant likelihoods of having LFS. For patients with LFS, there are recommended measures for prevention and early detection of LFS-associated cancers and cascade GT of relatives for LFS. Although co-existing genetic variants in NSCLC are not currently used as a biomarker for GT to identify patients with PGVs, given the evidence reviewed here, select patients with NSCLCs that harbor this dual biomarker (i.e., co-existing TP53/EGFR variants) might reasonably be considered for GT for LFS.
The invention discloses an application of a scutellaria flavone active ingredient and a preparation thereof in preparing a medicament for preventing and/or treating inflammation storm. The active ingredient of the baicalein is selected from at least one of the following components: baicalein, wogonin and oroxylin A. Inflammatory storm is an excessive immune response and inflammatory response of the body to external stimuli, characterized by a rapid and massive release of inflammatory cytokines. Inflammatory storms can be caused by a number of infectious or non-infectious diseases and are closely related to the severity of the disease and the occurrence of multiple organ dysfunction syndromes. Reducing the incidence of inflammatory storms helps to reduce organ damage and slow the progression of the disease, especially in critically ill patients. The invention discovers that baicalein, wogonin and oroxylin A all have the functions of inhibiting the mouse cytokine storm to different degrees. Baicalein can improve lung injury and inflammatory cell infiltration caused by inflammatory storm. Therefore, the active ingredient of the baicalein can be used for preparing the medicine for preventing and treating the inflammatory storm.
The invention facilitates a setting operation relating to the displaying and laying out of images and arranges it so that the layout will reflect the preferences of the observer. The invention provides a medical image display apparatus for displaying medial images and other medical data on a display unit. An image storage unit for storing medical images and a processor are connected to the display unit. A frequency-of-use storage unit and a mode storage unit are connected to the processor. When medical images have been displayed, the frequency-of-use storage unit stores the frequency of use of the layout type. The apparatus sets a display format of the medical images automatically based upon the frequency of use of this layout type. There is a good possibility that a layout type having a high frequency of use will reflect the preference of the reader (observer). If this layout type is used as is, or if the layout type is used after only a minor change, this will facilitate the setting operation relating to display layout.
The invention can wrap the medical device, in particular can wrap the implantable medical device, so as to minimize or substantially eliminate the reaction that the biological organism responds to the medical device which is introduced into the biological organism. The invention can wrap the medical device with various biocompatible materials. Curative medicine, medicament or compound can be mixed with the biocompatible materials, and be fixed on at least one part of the medical device. The curative medicine, medicament or compound can also further reduce the reaction that the biological organism responds to the medical device which is introduced into the biological organism. In addition, the curative medicine, medicament or compound can also be used for promoting concrescence, including the formation of blood clots. The curative medicament can also be transmitted to the diseased sites. During the process of partial transmission, liquid preparation can be expected to increase the validity and the transmission capacity of specific medicine, as well as to improve the device for promoting endothelialization. Different materials and wrapping methods can be used for keeping the medicine, the medicament or the compound to be positioned on the medical device until the medicine, the medicament or the compound are transmitted or positioned. In addition, the device for transmitting the implantable medical device can be improved for reducing the possibility of damaging the implantable medical device during the period of unwrapping.
The invention relates to the complete cDNA sequences of the Alternaria alternata allergenes Alt a 45 and Alt a 12. It has been possible in the course of molecular biological analysis of the allergens to identify Alt a 45 as a protein-disulphide isomerase. This protein is a 45 kD large protein to which 47 % of patients react and is thus an important primary allergen. Alt a 12 (to which 8 % of patients react) was identified as a ribosomal protein which is of interest because auto-antibodies for ribosomal proteins are found in patients suffering from lupus. It remains to be seen whether there is any connection between allergy to mould fungus and autoimmune diseases. Using this recombinant sequence and computer analysis, it has been possible to identify highly potent B- and T-cell epitopes and to use the peptides derived from the recombinant proteins for diagnosis of an allergy to Alternaria alternata mould fungus. The peptides has also proved suitable for both in vitro and in vivo allergen-specific stimulation of T-cells (proliferation, interleukin production), and for blocking the T-cells resulting in a tolerance of the allergen-specific T-lymphocytes.
Clonidine may potentiate the CNS-depressive effects of alcohol, barbiturates or other sedating drugs. If a patient receiving clonidine hydrochloride is also taking tricyclic antidepressants, the hypotensive effect of clonidine may be reduced, necessitating an increase in the clonidine dose. If a patient receiving clonidine is also taking neuroleptics, orthostatic regulation disturbances (e.g., orthostatic hypotension, dizziness, fatigue) may be induced or exacerbated.

Monitor heart rate in patients receiving clonidine concomitantly with agents known to affect sinus node function or AV nodal conduction, e.g., digitalis, calcium channel blockers, and beta-blockers. Sinus bradycardia resulting in hospitalization and pacemaker insertion has been reported in association with the use of clonidine concomitantly with diltiazem or verapamil. 

Amitriptyline in combination with clonidine enhances the manifestation of corneal lesions in rats (See Toxicology).

Based on observations in patients in a state of alcoholic delirium it has been suggested that high intravenous doses of clonidine may increase the arrhythmogenic potential (QT-prolongation, ventricular fibrillation) of high intravenous doses of haloperidol. Causal relationship and relevance for clonidine oral tablets have not been established.
Omalizumab was administered subcutaneously every 2 or 4 weeks over a period of 60 weeks to participants classified as having moderate to severe asthma. Doses (mg) and dosing frequency were determined by serum total IgE level (IU/mL) and body weight (kg). Also, participants continued with their conventional asthma therapy according to the National Asthma Education and Prevention Program (NAEPP-II, 2002) guidelines, under the management of an asthma specialist health care provider.
Of the 564 patients treated with PADCEV in combination with pembrolizumab, 44% (n=247) were 65-74 years and 26% (n=144) were 75 years or older. Of the 720 patients treated with PADCEV as a single agent in clinical trials, 39% (n=282) were 65-74 years and 24% (n=170) were 75 years or older. No overall differences in effectiveness were observed between patients 65 years of age or older and younger patients. 

Patients 75 years of age or older treated with PADCEV in combination with pembrolizumab experienced a higher incidence of fatal adverse reactions than younger patients. The incidence of fatal adverse reactions was 4% in patients younger than 75 and 7% in patients 75 years or older. 

Patients 75 years of age or older treated with PADCEV as a single agent experienced a higher incidence of fatal adverse reactions than younger patients. The incidence of fatal adverse reactions was 6% in patients younger than 75 years, and 11% in patients 75 years or older.

No significant difference was observed in the pharmacokinetics of PADCEV between patients 65 years and older and younger patients [see Clinical Pharmacology (12.3)].
BACKGROUND: Complications following head and neck microvascular free tissue transfer (MFTT) are common. Less is known about when they occur.
METHOD: Retrospective study of patients with primary or recurrent head and neck cancer undergoing MFTT reconstruction at a tertiary care institution. MFTT reconstructions with inpatient postoperative complications were included. The Kruskal-Wallis test was used to compare median postoperative day (POD) onset of complication by flap type.
RESULTS: Of 1090 patients undergoing MFTT reconstruction, 126 (11.6%) patients experienced inpatient complications including fibula (n = 35), anterolateral thigh (n = 60), or radial forearm (n = 31) MFTTs. POD onset was shortest for surgical site hematoma (median = 1 [IQR 1-5]), and longest for donor site infection (median = 11.5 [IQR 8-15]). There was no significant difference between flap types and POD onset of complications (p > 0.05).
CONCLUSION: Hematoma formation and flap failure occur earliest during hospitalization, while dehiscence, infection, and fistula occur later. There is no difference in complication timing between flap types.